

Apposite Capital Makes New Investment in NIMGenetics

London, UK – 10th May 2017. Apposite Capital, the private equity firm specialising in healthcare, today announces that it has made an initial investment of €7 million in NIMGenetics, a leading genetic diagnostic laboratory based in Spain. The company is operating in a fast-growing market and generated 34% in revenue growth last year. Apposite's investment will enable NIMGenetics to further develop its service offering as well as support its international expansion especially in Latin America.

NIMGenetics is a leading provider of genetic testing services in Spain. It uses the latest genomic technologies to offer first-in-class products and services in a number of medical areas including Pre-natal testing, Gynaecology, Neurology, Paediatrics, Cardiology and Oncology. The company was created in 2008 and currently serves over 500 medical centres and c1500 clinicians, mainly in Spain and Latin America.

The Global Genetic Testing Market is one of the fastest growing areas in healthcare and is poised to grow over 10% per annum in the next decade to reach approximately \$10.3 billion by 2025¹. It offers considerable medical applications such as early and precise diagnosis, better understanding of the predisposition for diseases and better understanding of individuals' reaction to a particular drug.

David Porter, Managing Partner at Apposite Capital, who is also joining the Board of Directors, commented: "NIMGenetics is at the forefront of genetic innovation and excellence in the provision of the genetic laboratory services. We believe it represents an ideal platform to take advantage of the extremely attractive clinical genetics and pharmacogenomics markets. Together with the management team, we look forward to further expanding its services capabilities and international footprint."

Enrique Samper Rodríguez, CEO of NIMGenetics, said: "Apposite's investment will help strengthen our leadership position in the field of genetic diagnostics. It will also support the growth of our company not only nationally but also internationally, positioning NIMGenetics as a worldwide provider of genetic diagnostic services with a broad catalogue of products and services across the following areas: prenatal, gynaecology, neurology, paediatrics and oncology.

Clinical genetics is now becoming widely available and will make high-quality, efficient and cost-effective health outcomes possible".

NIM Genetics represents the third investment from Apposite Healthcare Fund II.

- END -

¹ Source: Howe Sound Research & Grand View Research

Media contact:

Valerie Auffray

Tel: +44(0) 20 3475 1710

Email: valerie.auffray@appositecapital.com

About Apposite Capital

www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on healthcare.

The firm operates at the small end of the private equity market, providing both capital and expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of care provision and which have the potential of becoming market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally coupled with local insights, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies.

Apposite was created in 2006 and is headquartered in London, UK.

About NIMGenetics

<https://www.nimgenetics.com>

NIMGenetics is a leading Spanish laboratory specializing in genetic diagnosis. It uses the latest DNA microarrays, Next Generation Sequencing and FISH probes to diagnose disorders across different medical applications in different areas (Gynaecology, Paediatrics and Neuropaediatrics, Oncohematology, etc.). The company is headquartered in Madrid, Spain, and is expanding into Latin America.